A news summary of a 2025 FDA-funded RCT (Florian et al., JAMA Internal Medicine) reports liver enzyme elevations in 5.6% of healthy adults taking consumer-range CBD doses, with reversible effects and no serious adverse events. Here is what the evidence actually shows—and what it does not.